United Therapeutics CORP Form 4 insider transactions

President and COO Michael Benkowitz transferred 11,728 stock options to a family trust.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a transaction involving the acquisition of 9,500 common shares on May 12, 2026, under a 10b5-1 trading plan.

Nilda Mesa, a Director at United Therapeutics Corp., reported the sale of 258 shares of common stock on May 12, 2026, for $581.935 per share.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of stock transactions on May 8, 2026, involving the exercise of stock options and subsequent sale of common stock under a 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock on May 7, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of stock transactions on May 7, 2026, involving the exercise of stock options and subsequent sale of common stock.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock on May 7, 2026, under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the sale of common stock executed under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the exercise of stock options and sale of 10,000 shares of common stock on May 4, 2026, as part of a pre-arranged trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on May 1, 2026, under a Rule 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock on April 28, 2026, under a Rule 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock, acquired through option exercise, and the disposal of additional shares, all executed under a pre-arranged Rule 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Christopher Patusky exercised 1,000 stock options and sold the resulting shares under a 10b5-1 plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.